Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
The Brain’s Hidden “Pain Switch”: A Breakthrough for Millions Living with Chronic Pain
Mohamad-Ali Salloum, PharmD • October 29, 2025
Share
Brain research • Chronic pain
🧠 The Brain’s Hidden “Pain Switch” — a new way to think about chronic pain
When survival takes priority (like hunger or fear ), the brain can dampen persistent pain via Y1 receptor neurons in the lateral parabrachial nucleus (lPBN).
50M+
People in the U.S. live with chronic pain
Magnitude indicator
NPY → Y1
Neuropeptide Y signaling can suppress pain state
Therapeutic potential
What did scientists discover?
Teams from the University of Pennsylvania, University of Pittsburgh, and Scripps Research identified an ensemble of Y1 receptor (Y1R) neurons in the lPBN that become persistently active during long-term pain—but are inhibited when need states like hunger, thirst, or threat arise.
🔎 See the “control tower” in context
The lPBN is a brainstem hub that integrates sensory input (including nociception) with affective/motivational states, helping the brain prioritize survival needs over ongoing pain.
Key insight:
Pain “state” is not only peripheral—it’s encoded centrally. Turning down this state may require targeting brain circuits, not just the original injury site.
How does this “switch” work?
When you’re hungry or threatened, neurons release neuropeptide Y (NPY) , which binds to Y1 receptors on the lPBN ensemble to reduce its pain-sustaining activity—allowing attention to shift toward survival.
🧪 Real‑life analogy
Dog starts chasing you → you sprint → your nagging knee pain fades for a moment. That transient relief reflects top‑down reprioritization via NPY→Y1 signaling.
“There are circuits in the brain that can reduce the activity of neurons that transmit the signal of pain.”
Schematic: activity decreases as NPY increases during need states.
Why is this important?
Chronic pain affects tens of millions and can persist long after tissue healing. These findings shift focus from local tissues to central circuits that maintain the pain state—opening routes to biomarkers, brain‑targeted therapies, and NPY/Y1‑focused drug discovery.
- Reframe: Persistent pain can be a maintained brain state, not only ongoing damage.
- Targets: Y1 neurons and NPY pathways offer pharmacological and neuromodulation angles.
- Measurement: Imaging and electrophysiology could provide objective pain biomarkers.
#tryTry a safe, science‑aligned mini‑practice ↓
In preclinical work, activating need states (e.g., hunger cues) reduced persistent pain behaviors; blocking Y1 neurons reversed relief.
What’s next in research?
Active directions include Y1‑selective ligands , NPY modulation , and circuit‑level biomarkers via imaging. Structural insights into Y1 receptor binding may accelerate rational drug design.
🧬 Drug & gene‑target ideas
- Small‑molecule or peptide agonists that bias Y1 signaling toward analgesia.
- Gene therapy concepts to enhance NPY availability in relevant circuits (preclinical).
- Closed‑loop neuromodulation using circuit biomarkers (emerging clinical tech).
Can we activate this switch naturally?
Some behaviors engage overlapping survival/attention circuits and may complement medical care. Evidence and plausibility suggest trying these, within personal limits and clinician guidance:
- Brief, intense exercise (30–120s bouts) to create a salient competing state. Low risk
- Mindfulness/attention training to down‑weight nociceptive salience.
- Cold exposure (short, safe, controlled) as a strong interoceptive signal.
- Time‑restricted eating (if appropriate) to tap hunger‑linked circuits.
These are adjunctive ideas—evidence is evolving; consult a clinician for chronic conditions.
🎯 Micro‑practice: 2‑minute focus shift
- Choose a gentle but attention‑capturing task (e.g., 60–90s brisk steps in place).
- During the bout, track breaths and footfalls (count to 100, reset, repeat).
- Notice pain before → during → 2 minutes after. Log any change in intensity or “presence.”
The big picture
This line of research reframes chronic pain as a prioritization problem in the brain. If we can safely harness the brain’s own circuits—the Y1 “hub” and NPY signaling—chronic pain may become far more manageable than we once thought.
References:
- Goldstein N, Maes A, Allen HN, Nelson TS, Kruger KA, Kindel M, et al. A parabrachial hub for need-state control of enduring pain. Nature. 2025;586(7962):9602. Available from: https://www.nature.com/articles/s41586-025-09602-x [nature.com]
- Peeples L. Brain area linked to chronic pain discovered — offering hope for treatments. Nature News. 2025 Oct 8; Available from: https://www.nature.com/articles/d41586-025-03272-5 [nature.com]
- Nelson TS, Sinha GP, Santos DFS, Jukkola P, Prasoon P, Winter MK, et al. Spinal neuropeptide Y Y1 receptor-expressing neurons are a pharmacotherapeutic target for the alleviation of neuropathic pain. Proc Natl Acad Sci U S A. 2022;119(46):e22043228. [jstor.org]
- Betley JN, Goldstein N, Taylor BK. Scientists uncover the brain’s hidden pain switch. SciTechDaily. 2025 Oct 13; Available from: https://scitechdaily.com/scientists-uncover-the-brains-hidden-pain-switch/ [scitechdaily.com]
- Taylor BK, Nie AA. The pharmacotherapeutic potential of neuropeptide Y for chronic pain. J Intern Med. 2025; doi:10.1111/joim.20118. Available from: https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.20118 [onlinelibr....wiley.com]
- Park C, Kim J, Ko SB, Choi YK, Jeong H, Woo H, et al. Structural basis of neuropeptide Y signaling through Y1 receptor. Nat Commun. 2022;13:28510. Available from: https://www.nature.com/articles/s41467-022-28510-6 [nature.com]
- Neuroscience News. Hunger, fear, and the brain’s hidden switch to turn off chronic pain. Neuroscience News. 2025 Oct 8; Available from: https://neurosciencenews.com/hunger-fear-pain-brainstem-29792/ [neurosciencenews.com]
- ScienceDaily. Scientists discover brain circuit that can switch off chronic pain. ScienceDaily. 2025 Oct 10; Available from: https://www.sciencedaily.com/releases/2025/10/251009033126.htm [sciencedaily.com]
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
Discover the best ways to learn new skills
Stuck in your head? Discover why overthinking feels productive, how it sabotages your performance, and simple ways to shift into real action.
References: Wood W, Quinn JM, Kashy DA. Habits in everyday life: Thought, emotion, and action. J Pers Soc Psychol . 2002;83(6):1281–1297. Wood W, Neal DT. The habitual consumer. J Consum Psychol . 2009;19(4):579–592. Neal DT, Wood W, Labrecque JS, Lally P. How do habits guide behavior? Perceived and actual triggers of habits in daily life. J Exp Soc Psychol . 2012;48(2):492–498. Wood W, Mazar A, Neal DT. Habits and goals in human behavior: Separate but interacting systems. Perspect Psychol Sci . 2021;16(1):1–16. Graybiel AM. Habits, rituals, and the evaluative brain. Annu Rev Neurosci . 2008;31:359–387. Smith KS, Graybiel AM. Habit formation. Dialogues Clin Neurosci . 2016;18(1):33–43. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci . 2006;7(6):464–476. Graybiel AM. The basal ganglia and chunking of action repertoires. Neurobiol Learn Mem . 1998;70(1–2):119–136. Schultz W. Dopamine reward prediction error coding. Dialogues Clin Neurosci . 2016;18(1):23–32. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science . 1997;275(5306):1593–1599. Nasser HM, Calu DJ, Schoenbaum G, Sharpe MJ. The dopamine prediction error: Contributions to associative models of reward learning. Front Psychol . 2017;8:244. Kahnt T, Schoenbaum G. The curious case of dopaminergic prediction errors and learning associative information beyond value. Nat Rev Neurosci . 2025;26:169–178. Lally P, van Jaarsveld CHM, Potts HWW, Wardle J. How are habits formed: Modelling habit formation in the real world. Eur J Soc Psychol . 2010;40(6):998–1009. American Psychological Association. Harnessing the power of habits. Monitor Psychol . 2020;51(8):78–83.
References: Baddeley A. Working memory: theories, models, and controversies. Annu Rev Psychol . 2012;63:1–29. Chai WJ, Abd Hamid AI, Malin Abdullah J. Working memory from the psychological and neurosciences perspectives: a review. Front Psychol . 2018;9:401. Rogers RD, Monsell S. Costs of a predictable switch between simple cognitive tasks. J Exp Psychol Gen . 1995;124(2):207–231. Rubinstein JS, Meyer DE, Evans JE. Executive control of cognitive processes in task switching. J Exp Psychol Hum Percept Perform . 2001;27(4):763–797. Garner KG, Dux PE. Knowledge generalization and the costs of multitasking. Nat Rev Neurosci . 2023;24:98–112. Zhou X, Lei X. Wandering minds with wandering brain networks. Neurosci Bull . 2018;34(6):1017–1028. Sorella S, Crescentini C, Matiz A, et al. Resting‑state default mode network variability predicts spontaneous mind‑wandering. Front Hum Neurosci . 2025;19:1515902. Sweller J. Cognitive load during problem solving: effects on learning. Cogn Sci . 1988;12(2):257–285.
Why do we procrastinate even when tasks matter most? Discover the emotional roots of procrastination and how to stop
Confidence and self-esteem are often confused but are psychologically distinct. Learn how they differ, how each develops, and why understanding both matters for real growth.
Confidence isn’t about eliminating fear—it’s about acting despite it. Discover how courage, discomfort, and psychological growth build real confidence over time.
References: McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med . 2014;371(11):993–1004. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med . 2007;357:2109–2122. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med . 2008;358:1431–1443. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358:2545–2559. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med . 1991;324:781–788. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on cardiovascular and renal outcomes. N Engl J Med . 2020;383:1413–1424. Ioannidis JPA. Surrogate endpoints in clinical trials: are we being misled? BMJ . 2013;346:f314.
References: Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci . 2015;16(7):403‑18. Frisaldi E, Shaibani A, Benedetti F, Pagnini F. Placebo and nocebo effects associated with pharmacological interventions: an umbrella review. BMJ Open . 2023;13:e077243. Colloca L, Finniss D. Nocebo effects, patient‑clinician communication, and therapeutic outcomes. JAMA . 2012;307(6):567‑8. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a blinded, randomized trial of statin, placebo, and no treatment. N Engl J Med . 2021;385(23):2180‑9. Penson PE, Mancini GBJ, Toth PP, et al. Introducing the “drucebo” effect in statin therapy. J Cachexia Sarcopenia Muscle . 2018;9(6):1023‑33. Barnes K, Faasse K, Geers AL, et al. Can positive framing reduce nocebo side effects? Front Pharmacol . 2019;10:167. Caliskan EB, Bingel U, Kunkel A. Translating knowledge on placebo and nocebo effects into clinical practice. Pain Rep . 2024;9(2):e1142. von Wernsdorff M, Loef M, Tuschen‑Caffier B, Schmidt S. Effects of open‑label placebos in clinical trials: a systematic review and meta‑analysis. Sci Rep . 2021;11:3855.
References: Zaniletti I, Larson DR, Lewallen DG, Berry DJ, Maradit Kremers H. How to distinguish correlation from causation in orthopaedic research. J Arthroplasty. 2023;38(4):634–637. Rush J, Ajami M, Look KA, Margolis A. Statistics review part 10: causality and confounding. J Pharm Soc Wis. 2014;17(1):45–52. Koopmans E, Schiller C. Understanding causation in healthcare: an introduction to critical realism. Qual Health Res. 2022;32(8–9):1207–1214. Kahlert J, Gribsholt SB, Gammelager H, Dekkers OM, Luta G. Control of confounding in the analysis phase – an overview for clinicians. Clin Epidemiol. 2017;9:195–204. Shi AX, Zivich PN, Chu H. A comprehensive review and tutorial on confounding adjustment methods for estimating treatment effects using observational data. Appl Sci (Basel). 2024;14(9):3662. Gao Y, Xiang L, Yi H, Song J, Sun D, Xu B, et al. Confounder adjustment in observational studies investigating multiple risk factors: a methodological study. BMC Med. 2025;23:132. Ho FK, Brown J, Galwey NW. Regression adjustment for causal inference. BMJ Med. 2025;4:e000816. Correia LCL, Mascarenhas RF, Menezes FSC, Oliveira Junior JS, Vaccarino V, Ross JS, et al. Confounder selection in observational studies in high‑impact medical and epidemiological journals. JAMA Netw Open. 2025;8(7):e2524176.